• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 2nd August 2016

OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development

The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this post summarises their activity.

The 36th Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”.

Several members of the OHE team attended and contributed to the conference. This post contains a summary of their activity.

Multi-Indication Pricing: Pros, Cons and Applicability to the UK by Jorge Mestre-Ferrandiz

Multi-indication pricing (MIP) involves setting a different price for each indication approved for a medicine. The objective of this work was to outline the pros and cons of MIP, and its potential applicability in the UK. The analysis was partly based on a workshop with stakeholders, including HTA agencies, pharmacists, economists and clinicians.

Multi-Indication Pricing: Pros, Cons and Applicability to the UK from Office of Health Economics

 

Equity Adjusted QALYs? QALYs and Equity by Adrian Towse

Adrian Towse presented on Equity Adjusted QALYs? QALYs and Equity. In this presentation he:

  • Looked at definitions of equity, drawing on work by Tony Culyer;
  • Gave his view of lessons from the England value-based pricing (VBP) saga in which practical ways of implementing severity and societal impact adjustments to QALYs were identified but rejected;
  • Concluded that moving from listing the things that matter to measuring them to weighting them are three very different steps. Weighting in any form makes the Social Welfare Function explicit and will inevitably generate a backlash. A fair process is therefore required which combines elements of societal weighting which are quantified with a structured deliberative decision making process.

The presentation also looked at the Capability Approach; “What should be in the Value Framework?” and the use of Extended CEA to take account of income inequality in Middle and Low Income Countries.

Equity Adjusted QALYs? QALYs and Equity from Office of Health Economics

 

Modelling the Value of Early Access Schemes and Adaptive Pathway Approaches by Mikel Burdud

A range of early access agreements and adaptive pathways have been implemented in the last 15 years to expedite the development/licensing of promising new medicines. The aims of such policies are to provide timely access to medicines for patients with high unmet medical need and to incentivise innovation and R&D.

Berdud and colleagues model existing early access and adaptive pathway policies for a real case study. They assess the impact of the policies from the perspective of a range of stakeholders.

The conference slides are not available, but a full report of the study is forthcoming.

Options for Formulary Development in Middle-Income Countries by Karla Hernandez-Villafuerte

A number of middle-income countries (MICs) are evolving their health systems toward universal health coverage for patient populations. Such countries often have limited drug formularies and some form of essential drugs list. This presentation explores options for bridging the organisation of the health system and its priorities, and provides a framework for developing drug formularies.

OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES from Office of Health Economics
  • Drug Development/R&D
  • Economics of Innovation
  • Presentations

Related News

  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
  • News
  • March 2020

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Read more
  • News
  • January 2020

Funding Challenges in the Malaysian Health Care System

Read more
  • News
  • January 2020

OHE at HESG Winter 2020

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!